Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00548171
First received: October 22, 2007
Last updated: March 27, 2014
Last verified: February 2011

October 22, 2007
March 27, 2014
November 2007
April 2008   (final data collection date for primary outcome measure)
  • In Group A:- Anti-diphtheria antibody concentrations [ Time Frame: One month after the booster dose ] [ Designated as safety issue: No ]
  • In Group A:- Anti-tetanus antibody concentrations [ Time Frame: One month after the booster dose ] [ Designated as safety issue: No ]
one month after the booster dose: anti-diphtheria and anti-tetanus antibody concentration
Complete list of historical versions of study NCT00548171 on ClinicalTrials.gov Archive Site
  • In all subjects:- Anti-diphtheria antibody concentration [ Time Frame: Prior to booster vaccination ] [ Designated as safety issue: No ]
  • Anti-tetanus antibody concentrations [ Time Frame: Prior to booster vaccination ] [ Designated as safety issue: No ]
  • Anti-pertussis antibody concentrations [ Time Frame: Prior to and 1 month after booster vaccination ] [ Designated as safety issue: No ]
  • Booster response to pertussis antigens [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
  • Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
  • Occurrence of unsolicited symptoms [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
  • Occurrence of serious adverse events [ Time Frame: Following booster vaccination ] [ Designated as safety issue: Yes ]
anti-diphtheria, anti-tetanus, anti-pertussis antibody conc (before and 1 month post vacc) sol (4 days) and unsol (31 days) symptoms, SAEs
Not Provided
Not Provided
 
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination
Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting.

The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a previous clinical study. Only subjects who received the booster vaccination in a previous clinical study are eligible for participation in this study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

No new recruitment will be performed in this booster phase (see inclusion criteria)

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Acellular Pertussis
  • Tetanus
  • Diphtheria
Biological: Boostrix™
Intramuscular injection, 1 dose
  • Experimental: Group A
    Subjects who had received the dTpa vaccine in study 263855/002
    Intervention: Biological: Boostrix™
  • Active Comparator: Group B
    Subjects who had received the Td + pa vaccines in either sequences (i.e. Td vaccine followed by the pa vaccine or pa vaccine followed by the Td vaccine) in study 263855/002
    Intervention: Biological: Boostrix™
Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine. 2010 Dec 10;29(1):45-50. Epub 2010 Oct 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
205
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/002 .
  • A male or female subject, recruited 10 years (+/- 9 months) after booster vaccination in study 263855/002.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of booster vaccination.
  • Written informed consent obtained from the subject.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • Previous booster vaccination against diphtheria, tetanus or pertussis since the last dose received in study 263855/002
  • History of diphtheria, tetanus, or pertussis diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
  • Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :- hypersensitivity reaction to any component of the vaccine; - encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; - fever ≥ 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause; - collapse or shock-like state within 48 hours of vaccination; - convulsions with or without fever, occurring within 3 days of vaccination.
  • Acute disease at the time of enrolment.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
Both
28 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00548171
110804
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP